novo-share-votes-4.html
Novo Annual Review 2016
5 / 71
novo
a/s n ovo a/s is a danish private limited liability company fully owned by the novo nordisk
foundation. it is the holding company of the novo group
and the controlling shareholder in the publicly listed companies, novo nordisk a/s and novozymes a/s, and together with novo nordisk in nnit a/s. novo a/s was established in 1999 prior to the demerger of novo nordisk, where novozymes was established as a stand-alone, publicly listed company. novo a/s? objectives are to meet the novo nordisk foundation?s strategic and commercial goals. we do so by being a strong owner of the companies in the novo group, and by: ? complying with the rules and principles that are set out in the statutes of the novo nordisk foundation regarding exercise of the voting rights of a and b shares in novo nordisk and novozymes, respectively; ? always maintaining a material influence on novo nordisk and novozymes; and ? maintaining a liquid buffer to support any investment needs in the novo group. by investing in the life science sector, novo a/s can meet the commercial objectives of the novo nordisk foundation and ensure value creation because the novo group has a unique heritage and purpose within life science. novo a/s? capabilities as investor include life science investment competences, a strong industry network, financial strength, and a long-term investment horizon. novo a/s? investment objectives are to: ? generate competitive financial returns; ? be a responsible investor; ? help to address unmet medical needs; and ? generate broader support for the life science industry. the common denominator for all novo a/s? investments is that they must comply with ? or at least not act against ? the values and commitments defined in the charter for companies in the novo group and novo a/s? governance framework. 5 novo a/s
novo-2016-investments-6.html
